Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:activities |
immune checkpoint inhibition
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:clinical_trial |
Phase 1
|
| gptkbp:developed_by |
Alchemab Therapeutics
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-0737
|
| gptkbp:indication |
solid tumors
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:status |
under investigation
|
| gptkbp:targets |
gptkb:PD-1
|
| gptkbp:type |
gptkb:monoclonal_antibody
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
4
|